Kyverna Therapeutics (KYTX) Cash from Operations (2023 - 2026)
Kyverna Therapeutics (KYTX) posted Cash from Operations of 41597000.0 for Q1 2026, down 24.11% on a QoQ basis from 33515000.0 in Q4 2025, and up 7.36% year-over-year from 38746661.0 in Q1 2025.
Kyverna Therapeutics (KYTX) Cash from Operations (2023 - 2026) Analysis & Trends
Kyverna Therapeutics' Cash from Operations history runs 4 years deep, the most recent figure standing at 41597000.0 for Q1 2026.
- Quarterly Cash from Operations rose 7.36% year-over-year to 41597000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 150397000.0 (down 12.55% YoY) and the FY2025 annual result came in at 153700000.0, down 34.53% from the prior year.
- Cash from Operations was 41597000.0 for Q1 2026 at Kyverna Therapeutics, down from 33515000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 11132000.0 in Q3 2023 and bottomed at 44900000.0 in Q1 2025.
- A 4-year average of 27842846.15 and a median of 27489000.0 in 2024 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2024 — Cash from Operations plunged 146.94% — and 2025, when it climbed 9.57%.
- Kyverna Therapeutics' Cash from Operations stood at 18563000.0 in 2023, then tumbled by 99.65% to 37061000.0 in 2024, then grew by 9.57% to 33515000.0 in 2025, then decreased by 24.11% to 41597000.0 in 2026.
- Business Quant data shows KYTX's Cash from Operations at 41597000.0 in Q1 2026, 33515000.0 in Q4 2025, and 43321000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Kyverna Therapeutics | 440.57 Mn | 440.57 Mn | - | -41.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -41.60 Mn |
| Mar 31, 2026 | -41.60 Mn |
| Dec 31, 2025 | -33.52 Mn |
| Dec 31, 2025 | -33.52 Mn |
| Sep 30, 2025 | -43.32 Mn |
| Sep 30, 2025 | -43.32 Mn |
| Jun 30, 2025 | -31.96 Mn |
| Jun 30, 2025 | -31.96 Mn |
| Mar 31, 2025 | -44.90 Mn |
| Mar 31, 2025 | -44.90 Mn |
| Dec 31, 2024 | -37.06 Mn |
| Dec 31, 2024 | -37.06 Mn |
| Sep 30, 2024 | -27.49 Mn |
| Sep 30, 2024 | -27.49 Mn |
| Jun 30, 2024 | -24.18 Mn |
| Jun 30, 2024 | -24.18 Mn |
| Mar 31, 2024 | -25.53 Mn |
| Mar 31, 2024 | -25.53 Mn |
| Dec 31, 2023 | -18.56 Mn |
| Dec 31, 2023 | -18.56 Mn |